This pharmaceutical pipeline includes products developed by Allergan and products for which Allergan has marketing rights. Health care product development is an uncertain process. Products reach market only after meeting specific criteria for efficacy and safety.  There can be no assurance that any product undergoing clinical trials or pending regulatory approvals will be marketed. Product Disease Target Company Alliances collaborations Alpha Agonists Glaucoma/Neuropathic Pain Acadia Pharmaceuticals, Inc. Muscarinics  Glaucoma Acadia Pharmaceuticals, Inc. AZELEX Acne Berlex, Inc. Compound Screening Library General R&D Discovery Partners Neuromodulators Pain Centre for Applied Microbiology & Research (CAMR) Panzem Age Related Macular EntreMed, Inc. Degeneration  (ARMD) Drug Target Identification Pain, Ophthalmology ExonHit Therapeutics and Neurology ELESTAT Allergy Inspire Pharmaceuticals, Inc. ALOCRIL Allergy Procter & Gamble Pharmaceuticals, Inc. – General Practitioners (Canada) TAZORAC Gel and Cream Psoriasis and Acne Procter & Gamble Pharmaceuticals, Inc. – General Practitioners (U.S./Canada) ZORAC Gel Psoriasis and Acne Pierre Fabre Dermatologie (Europe) OCUFLOX Anti-Infective Daiichi/Santen Stage of Development Product Disease Target Technology Alliances Early Late Filed Approved dermatology Tazarotene Oral (U.S.) Moderate to Severe Psoriasis • • • AVAGE (U.S./Europe) Photodamage • • (E.U.) • • (U.S.) Peplin (PEP005) Actinic Keratosis Peplin Biotech Ltd. • Peplin (PEP005) Basal and Squamous Peplin Biotech Ltd. • Cell Carcinoma new technology  AGN 201904 (Proton Pump Inhibitor) Gastric Ulcers Winston Pharmaceuticals • AG N 199981 & 201781 Neural/Visceral Pain • (Al pha  A gonist ) AGN 203818 (Alpha Agonist) Neural/Visceral Pain •